Over-prescription of short-acting β₂-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study

Adel Khattaba Pulmonary Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptCorrespondence[email protected]

https://orcid.org/0000-0002-4253-0662

Ashraf Madkoura Pulmonary Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Anish Ambaramb Department of Pulmonology, Gateway Centre for Respiratory and Gastrointestinal Disease, Durban, South Africa

Clifford Smithc Morningside Mediclinic, Sandton, Johannesburg, South Africa

Chakaya J. Muhwad Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya;e Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Jared O. Mechaf Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya

Mohamed Alsayedg Medicinal Department, AstraZeneca, Dubai, United Arab Emirates

Maarten J. H. I. Beekmanh Respiratory & Immunology, AstraZeneca, The Hague, The Netherlands

show all

Over-prescription of short-acting β₂-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study

Supplemental_Material_CLEAN.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Over-prescription of short-acting β2-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study

Supplemental_Material_CLEAN.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Over-prescription of short-acting β₂-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study